Skip to main content
Publications
Phiri K, Hallas J, Linder M, Margulia A, Suehs B, Arana A, Bahmanyar S, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Sahlertz Kristiansen N, Appenteng K, de Vogel S, Seeger J. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Poster presented at the American Urological Association 2020 Conference (Conference cancelled); May 2020. Washington, DC. [abstract] J Urol. 2020 Apr; 203(Supplement 4):e910-1. doi: 10.1097/JU.0000000000000931.010
Mazurek M, Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Lu S, Lip GYH, GLORIA-AF Investigators. Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF phase II registry. Thromb Haemost. 2017 Dec;117(12):2376-88. doi: 10.1160/TH17-08-0555
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassils C, Nyirady J, Lebwohl M. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016 Apr;55(4):401-7. doi: 10.1111/ijd.13236
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab improves patient‐reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo‐controlled clinical trials. Int J Dermatol. 2016 Apr;55(4):401-7. doi: 10.1111/ijd.13236
Strober B, Zhao Y, Tran MH, Gnanasakthy A, Nyirady J, Papavassils C, Nelson LM, McLeod LD, Mordin M, Gottlieb A, Elewski B, Lebwohl M. Psychometric validation of the psoriasis symptom diary using phase III study data from patients with chronic plaque psoriasis. Int J Dermatol. 2016 Mar;55(3):e147-55. doi: 10.1111/ijd.13117
Morelli X, Foraster M, Aguilera I, Basagana X, Corradi E, Deltell A, Ducret-Stich R, Phuleria H, Ragettli MS, Rivera M, Thomasson A, Kunzli N, Slama R. Short-term associations between traffic-related noise, particle number and traffic flow in three European citie. Atmos Environ. 2015 Feb;103:25-33. doi: 10.1016/j.atmosenv.2014.12.012
Ragettli MS, Ducret-Stich RE, Foraster M, Morelli X, Aguilera I, Basagana X, Corradi E, Ineichen A, Tsai M, Probst-Hensch N, Rivera M, Slama R, Kunzli N, Phuleria HC. Spatio-temporal variation of urban ultrafine particle number concentrations. Atmos Environ. 2014 Oct;96:275-83. doi: 10.1016/j.atmosenv.2014.07.049
Basagana X, Rivera M, Aguilera I, Agis D, Bouso L, Elosua R, Foraster M, de Nazelle A, Nieuwenhuijsen M, Vila J, Kunzli N. Effect of the number of measurement sites on land use regression models in estimating local air pollution. Atmos Environ. 2012 Jul;54:634-42. doi: 10.1016/j.atmosenv.2012.01.064
Mannila MN, Silveira A, Hawe E, Eriksson P, Aillaud MF, Juhan-Vague I, Yudkin J, Margaglione M, di Minno G, Mussoni L, Tremoli E, Humphries S, Hamsten A, HIFMECH Study Group. Plasma fibrinogen concentration predicts the risk of myocardial infarction differently in various parts of Europe: effects of beta-fibrinogen genotype and environmental factors. The HIFMECH Study. Thromb Haemost. 2004 Dec;92(6):1240-9.
Konstantoulas C, Hawe E, Saut N, Yudkin JS, di Minno G, Margaglione M, Hamsten A, Humphries SE, Juhan-Vague I, Ireland H, HIFMECH Study Group. Common variants in the thrombomodulin gene as a risk for myocardial infarction in the north of Europe (HIFMECH Study). Thromb Haemost. 2004 Mar;91(3):628-30.
Kelberman D, Hawe E, Luong LA, Mohamed-Ali V, Lundman P, Tornvall P, Aillaud MF, Juhan-Vague I, Yudkin JS, Margaglione M, di Minno G, Tremoli E, Humphries SE, HIFMECH Study Group. HIFMECH study group. Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. The HIFMECH Study. Thromb Haemost. 2004;92(5):1122-8.